Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet
Microencapsulated potassium chloride
RxCUI: 1801294
What the CMS Formulary Data Shows for Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet
Per the CMS 2026 Part D formulary file, Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet (RxNorm concept RXCUI 1801294, generic name Microencapsulated potassium chloride) appears on 327 distinct formulary files spanning 5,055 Medicare Part D plan offerings - 99.8% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 1.6.
Real-world access to Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet today.
Coverage Details
- Formularies covering
- 327
- Plans covering
- 5,055
- Coverage rate
- 99.8%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet covered by Medicare Part D?
Yes, Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet is covered by 5,055 Medicare Part D plans (99.8% of all Part D formularies).
What tier is Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet on Medicare Part D plans?
Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet averages Tier 1.6 across Part D plans, ranging from Tier 1 to Tier 4.
Does Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet. Step therapy: 0%. Quantity limits: 0%.
Read our methodology - how this data is sourced, computed, and verified.